Maze Therapeutics (MAZE) Institutional Ownership $30.39 +0.49 (+1.64%) As of 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Maze Therapeutics (NASDAQ:MAZE)Number ofInstitutional Buyers(last 12 months)36TotalInstitutional Inflows(last 12 months)$280.77MNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$3.92M Get MAZE Insider Trade Alerts Want to know when executives and insiders are buying or selling Maze Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data MAZE Institutional Buying and Selling by Quarter Maze Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails10/23/2025 SG Americas Securities LLC5,015$130K0.0%N/A0.011% 8/15/2025Tower Research Capital LLC TRC 4,608$57K0.0%+452.5%0.011% 8/15/2025Octagon Capital Advisors LP177,667$2.18M0.5%-62.0%0.405% 8/15/2025Frazier Life Sciences Management L.P.4,567,275$56.04M2.2%+10.6%10.416% 8/15/2025Engineers Gate Manager LP10,212$125K0.0%N/A0.023% 8/15/2025Boothbay Fund Management LLC75,530$927K0.0%-22.1%0.172% 8/15/2025Bank of America Corp DE5,782$71K0.0%+33.6%0.013% 8/13/2025Invesco Ltd.18,430$226K0.0%-10.3%0.042% 8/13/2025CW Advisors LLC30,235$371K0.0%N/A0.069% 8/13/2025Virtus Investment Advisers LLC6,940$85K0.0%N/A0.016% Get the Latest News and Ratings for MAZE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Maze Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/12/2025Legal & General Group Plc4,242$52K0.0%+387.0%0.010% 8/12/2025JPMorgan Chase & Co.4,366$54K0.0%-56.9%0.010% 8/12/2025Ensign Peak Advisors Inc18,539$227K0.0%N/A0.042% 8/8/2025Geode Capital Management LLC231,237$2.84M0.0%+8.8%0.528% 7/25/2025 CWM LLC2,266$28K0.0%N/A0.005% 6/27/2025Goldman Sachs Group Inc.13,129$145K0.0%N/A0.030% 5/29/2025Rhumbline Advisers7,235$80K0.0%N/A0.017% 5/16/2025Woodline Partners LP929,102$10.23M0.1%N/A2.121% 5/16/2025Octagon Capital Advisors LP468,000$5.15M0.6%N/A1.069% 5/16/2025Goldman Sachs Group Inc.13,129$145K0.0%N/A0.030% 5/16/2025MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.5,135$57K0.0%N/A0.012% 5/16/2025ARCH Venture Management LLC4,120,053$45.36M22.0%N/A9.407% 5/16/2025Alyeska Investment Group L.P.125,000$1.38M0.0%N/A0.285% 5/15/2025Frazier Life Sciences Management L.P.4,129,001$45.46M2.1%N/A9.428% 5/15/2025Hhlr Advisors LTD.457,535$5.04M0.1%N/A1.045% 5/15/2025Ghisallo Capital Management LLC30,000$330K0.0%N/A0.068% 5/15/2025Driehaus Capital Management LLC132,115$1.46M0.0%N/A0.302% 5/14/2025Affinity Asset Advisors LLC250,000$2.75M0.3%N/A0.571% 5/14/2025Corebridge Financial Inc.4,328$48K0.0%N/A0.010% 5/14/2025Matrix Capital Management Company LP2,486,184$27.37M7.9%N/A5.677% 5/12/2025Nuveen LLC11,375$125K0.0%N/A0.026% 5/12/2025Invesco Ltd.20,552$226K0.0%N/A0.047% 5/9/2025Deutsche Bank AG8,885$98K0.0%N/A0.020% 5/9/2025TRV GP V LLC950,800$10.47M8.4%N/A2.171% 5/9/2025TRV GP IV LLC6,073,958$66.87M72.0%N/A13.869% 5/9/2025Charles Schwab Investment Management Inc.72,305$796K0.0%N/A0.165% 5/9/2025Harvard Management Co. Inc.637,528$7.02M0.6%N/A1.456% 5/2/2025Alphabet Inc.2,412,471$26.56M1.7%N/A5.508% 5/1/2025New York State Common Retirement Fund2,300$25K0.0%N/A0.005% 4/29/2025Bank of New York Mellon Corp17,233$190K0.0%N/A0.039% 4/23/2025Bessemer Group Inc.481,790$5.31M0.0%N/A1.100% 4/16/2025General Catalyst Group Management LLC1,035,910$11.41M1.3%N/A2.365% (Data available from 1/1/2016 forward) MAZE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of MAZE shares? During the previous two years, 38 institutional investors and hedge funds held shares of Maze Therapeutics. The most heavily invested institutionals were TRV GP IV LLC ($66.87M), Frazier Life Sciences Management L.P. ($56.04M), ARCH Venture Management LLC ($45.36M), Matrix Capital Management Company LP ($27.37M), Alphabet Inc. ($26.56M), General Catalyst Group Management LLC ($11.41M), and TRV GP V LLC ($10.47M).Learn more on Maze Therapeutics' institutional investors. Which institutional investors have been buying Maze Therapeutics' stock? Of the 36 institutional investors that purchased Maze Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: TRV GP IV LLC ($6.07M), Frazier Life Sciences Management L.P. ($4.57M), ARCH Venture Management LLC ($4.12M), Matrix Capital Management Company LP ($2.49M), Alphabet Inc. ($2.41M), General Catalyst Group Management LLC ($1.04M), and TRV GP V LLC ($950.80K). How much institutional buying is happening at Maze Therapeutics? Institutional investors have bought a total of 25,433,907 shares in the last 24 months. This purchase volume represents approximately $280.77M in transactions. Which of Maze Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Maze Therapeutics stock in the last 24 months: Octagon Capital Advisors LP ($290.33K), Boothbay Fund Management LLC ($21.44K), JPMorgan Chase & Co. ($5.78K), and Invesco Ltd. ($2.12K). How much institutional selling is happening at Maze Therapeutics? Institutional investors have sold a total of 319,668 shares in the last 24 months. This volume of shares sold represents approximately $3.92M in transactions. Related Companies Arcellx Institutional Ownership Protagonist Therapeutics Institutional Ownership Kymera Therapeutics Institutional Ownership Akero Therapeutics Institutional Ownership NewAmsterdam Pharma Institutional Ownership Crinetics Pharmaceuticals Institutional Ownership Viking Therapeutics Institutional Ownership Lantheus Institutional Ownership Mirum Pharmaceuticals Institutional Ownership Telix Pharmaceuticals Institutional Ownership This page (NASDAQ:MAZE) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
